指南与共识支持与姑息治疗

COVID-19大流行时代的肿瘤心脏病学诊疗:国际肿瘤心脏病学会声明

Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement.
指南 / 共识 · CA Cancer J Clin · 2020-09-10

该声明由国际肿瘤心脏病学会发布,阐述COVID-19大流行对肿瘤心脏病学领域的特殊影响,并提出诊疗路径调整策略。核心调整包括更多利用心脏生物标志物和更聚焦的心脏影像学方法,目标是在减少SARS-CoV-2感染风险的同时不忽视心血管疾病对肿瘤患者总体结局的重要影响。

要点

  • 合并心血管疾病和癌症的患者是COVID-19大流行中最脆弱的群体之一。
  • 建议转向更多使用心脏生物标志物和更聚焦的心脏影像学方法。
  • 策略调整旨在降低感染风险的同时不忽视心血管疾病管理。

核心结论

  • 合并癌症和心血管疾病的患者在大流行期间最为脆弱,需要统一而审慎的评估与管理方法。

研究设计与样本

  • 国际肿瘤心脏病学会(ICOS)发布的声明,综述病毒爆发对肿瘤心脏病学领域的独特影响并提出诊疗路径调整。

主要发现

  • 有心血管危险因素和确诊心血管疾病的患者最初被识别为严重并发症(包括死亡)最高危人群。
  • 后续研究指出癌症患者同样面临重症病程的高风险。

关键数值与推荐

  • 诊疗调整包括转向更多利用心脏生物标志物和更聚焦的心脏影像学方法。

临床怎么用

  • 在典型实践路径调整的背景下,采用更多心脏生物标志物和更聚焦的心脏影像学策略。
  • 目标是在最小化SARS-CoV-2感染(或未来其他病毒爆发)风险的同时,不忽视心血管疾病对肿瘤患者总体结局的重要影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has given rise to a pandemic of unprecedented proportions in the modern era because of its highly contagious nature and impact on human health and society: coronavirus disease 2019 (COVID-19). Patients with cardiovascular (CV) risk factors and established CV disease (CVD) are among those initially identified at the highest risk for serious complications, including death. Subsequent studies have pointed out that patients with cancer are also at high risk for a critical disease course. Therefore, the most vulnerable patients are seemingly those with both cancer and CVD, and a careful, unified approach in the evaluation and management of this patient population is especially needed in times of the COVID-19 pandemic. This review provides an overview of the unique implications of the viral outbreak for the field of cardio-oncology and outlines key modifications in the approach to this ever-increasing patient population. These modifications include a shift toward greater utilization of cardiac biomarkers and a more focused CV imaging approach in the broader context of modifications to typical practice pathways. The goal of this strategic adjustment is to minimize the risk of SARS-CoV-2 infection (or other future viral outbreaks) while not becoming negligent of CVD and its important impact on the overall outcomes of patients who are being treated for cancer.

来源:CA Cancer J Clin,查看原文。版权归原作者所有。

引用

  1. Lenihan D, Carver J, Porter C, et al. Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. CA Cancer J Clin. 2020. PMID: 32910493. doi:10.3322/caac.21635

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。